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Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disorder,   originating 
sporadically in the population aged over 65 years, and advanced age is the principal risk factor 
leading to AD development. In spite of the large amount of research going on around the globe 
and all the information now available about AD, there is still no origin or   triggering process 
known so far. Drugs approved for the treatment of AD include tacrine, donepezil, rivastigmine, 
galantamine, and memantine. These may delay or slow down the degenerative process for a 
while, but they can neither stop nor reverse its progression. Because that this might be due to a 
lack of effect of these drugs on degenerating neurons, even when they are able to potentiate the 
brain in nondegenerative conditions, we propose here an   alternative therapy consisting of initial 
repair of neuronal membranes followed by conventional drug therapies. The rehabilitation of 
neurons in a degeneration process would enable the drugs to act more effectively on them and 
improve the effects of treatment in AD patients.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder with loss of memory and 
other cognitive functions which progresses slowly, extending the disease for several 
years. Survival is very variable in these patients, although death often occurs within 
10 years of onset, often as a result of infections.
In more than 90% of cases, AD develops after the age of 65 years, and doubles 
its prevalence with every successive decade of life, from 10% at 60–70 years to 40% 
at 80 years of age. Several chromosomes have been shown to be implicated in the 
  pathology of AD, including chromosomes 1, 14, and 21, associated with the familial 
early-onset forms of the disease, and chromosomes 12 and 19, linked to   late-onset 
forms.1 However, most cases cannot be explained genetically, and thus several 
  hypotheses have been raised over the years in an attempt to explain this complex 
  disease, some of them suggesting the presence of unidentified infectious or toxic 
agents2 which modify the risk of developing AD.
One of the main processes leading to the symptomatology of AD is the abnormal 
phosphorylation of tau, a microtubule-associated protein. When tau gets hyperphos-
phorylated, it dissociates from microtubules, and structures called paired helical 
filaments begin to form within the cell bodies of neurons, generating neurofibrillary 
tangles, with hyperphosphorylated tau as their main component and leaving a loose 
cytoskeleton, which leads the neuronal membrane to lose its shape.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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According to the amyloid cascade hypothesis,3 β-amyloid 
peptide, the principal constituent of neuritic plaques, may 
have a major role in the neuropathology of AD. β-amyloid 
peptide generally exists in two forms, one is 40 amino acids 
long and the other is 42 amino acids long (Aβ40 and Aβ42, 
respectively), which differ in their terminal carbon structure. 
Of these two forms, Aβ42 is the most prone to aggregation.4 
Amyloid peptides are generated by the sequential actions of 
two enzymes, ie, β-secretase (BACE1) and γ-secretase.
BACE1 is widely expressed in the brain (mainly in the 
hypothalamus), and its involvement in the myelination pro-
cess of the peripheral nervous system has been established.5 
Even though the function of BACE1 is not fully understood 
as yet, recent studies demonstrate that it activates neuroreg-
ulin-1, thus having direct involvement in the myelination 
process.6 γ-secretase is a proteic presenilin complex, and one 
of its largest components is a protein known as nicastrin, the 
function of which has been widely associated with embryonic 
growth retardation and mortality.7
There is no cure for AD as yet, and drug therapies are 
not effective enough to avoid symptoms. For these reasons, 
we felt the need to come up with an alternative, accessible, 
and safe therapy able to augment conventional drug treat-
ments and have increased effectiveness in AD patients at any 
stage of the disease, but mainly in the first stages, where the 
rehabilitation of degenerating neurons could make a great 
difference to progression of the disease.
Drugs used for AD treatment
Five drugs have been approved for AD treatment in different 
stages of the disease, although they all show limited efficacy. 
These are tacrine, donepezil, rivastigmine, galantamine, and 
memantine.8 Tacrine was one of the first drugs to be used for 
memory loss and cognitive decline, often accompanied by 
abnormal behavior and physical debilitation in AD patients. 
The alleged success of tacrine in treating these symptoms 
was heralded as confirmation of the cholinergic theory 
of AD. Nevertheless, its efficacy remains controversial.9 
A   acetylcholinesterase inhibitor, tacrine has been associated 
with increased levels of transaminases in approximately 50% 
of the patients treated, but the mechanism by which it causes 
damage is not completely understood, and there could be 
genetic factors involved.10
Donepezil is another acetylcholinesterase inhibitor its 
selectiveness as an inhibitor is fairly specific. Donepezil 
is used for the treatment of moderate to severe AD,11 and 
is apparently well tolerated by patients and has few side 
effects.12 On the other hand, rivastigmine has shown fewer 
side effects and better acceptance by patients13 than donepezil. 
However, the effectiveness of donepezil has been limited in 
patients with AD.14
Galantamine, another member of the acetylcholinesterase 
inhibitor group, has shown a protective role for cortical 
neurons, preventing them from the cytotoxicity generated 
by aggregation of amyloid peptides.15,16
Unlike most drugs, memantine is not an acetylcholin-
esterase inhibitor, but an N-methyl-D-aspartate receptor 
  antagonist. It reduces clinical deterioration in moderate to 
severe AD, for which other treatments are not available. 
Recent studies carried out in transgenic mice show that 
memantine decreases the levels of amyloid peptide and 
prevents synaptic dysfunction.17 The activity of protein 
phosphatase (PP)-2A is compromised in the AD brain and 
is believed to be a cause of the abnormal hyperphosphory-
lation of tau and consequent neurofibrillary   degeneration. 
In those studies, memantine inhibits and reverses the 
PP-2A inhibition-induced abnormal hyperphosphoryla-
tion and accumulation of tau in organotypic cultures of rat 
hippocampal slices. Such restorative effects of memantine 
were not detected either with 5,7-dichlorokynurenic acid or 
with D(-)-2-amino-5-phosphopentanoic acid, N-methyl-D-
aspartate receptor antagonists, which are active at glycine 
and glutamate binding sites, respectively. The conclusions 
of these studies were that memantine inhibits and reverses 
PP-2A inhibition-induced abnormal hyperphosphorylation of 
tau/neurofibrillary degeneration, and that this drug might be 
useful for the treatment of AD and related tauopathies.19
Tau and β-amyloid peptides are the main contributors to 
the pathology of AD. Tau localizes via a 3´-UTR region in 
its mRNA with an axonic signal sequence.18,19 Because tau is 
overexpressed, a disturbance in axonal transport could cause 
hyperphosphorylation events, leading kinesin not to carry out 
antegrade transport properly,20,21 thus causing a disruption of 
molecular transport to the axon. Memantine and galantamine 
produce a reduction in amyloid aggregation,15,17 but show no 
apparent effect on paired helical filament formation.
Although these drugs increase the availability of the neu-
rotransmitter at the synaptic cleft, the neuronal membrane is 
damaged so, at best, they may slow progression of symptoms 
for a few months. This highlights a need to repair the neuronal 
membranes in order to rehabilitate degenerating neurons to 
respond better to drug treatments.
Neuronal restoration in AD patients
Why do the drugs available to treat AD have limited   efficacy? 
The answer might be simple. Most of these drugs are Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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  acetylcholinesterase inhibitors and allow the   neurotransmitter, 
acetylcholine, to remain for longer in the synaptic cleft. The 
problem we envisage is that degenerative neurons may not 
have their cholinergic receptors properly positioned on the 
damaged membrane, and there may even be some receptors 
not reaching the postsynaptic neuron during trafficking to the 
dendrite spine. Restoration of neuronal membranes before 
starting treatment with an acetylcholinesterase inhibitor 
might enhance the effects of the drugs to produce a prolonged 
improvement in symptomatology.
Omega-3 acids
Omega-3 acids have a role in inhibition of ischemic damage22 
and also in increased neurite development, demonstrated 
when hippocampal neurons are treated with docosahexaenoic 
acid. Omega-3 acids are also involved in the remodeling of 
membrane rafts23 and in neurogenesis.24 Rafts are microdo-
mains of cell membranes, are rich in cholesterol, and are 
associated with the stabilization of membrane receptors. 
Membrane rafts have also been shown to be involved in 
stabilizing the synapse, the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid25 and N-methyl-D-aspartate 
receptors,26 and appear to maintain dendritic spines. Rafts 
are also required for the proper clustering of acetylcholine 
receptors.27 When cell membranes are damaged by reactive 
oxygen species, as occurs in AD, there is a redistribution of 
lipids, such as cholesterol and sphingomyelin, because of an 
increase in membrane fluidity,28 and this can lead to changes 
in the positioning of membrane receptors.   Importantly, 
omega-3 acids have shown the ability to inhibit tau 
hyperphosphorylation,29 which would allow axonal transport 
restoration. It has been shown that omega-3 is also capable 
of reducing amyloid plaque formation.29,30
After neuronal membranes are restored, it would be 
necessary to re-establish the connections between neurons. 
This process could be aided by drugs like fluoxetine31 and 
escitalopram,32 which promote serotonin reuptake. It has been 
suggested that good recapture of serotonin has a role in the 
formation of new synapses and neuronal reconnections.
Folic acid
Folic acid has an important role in neuroplasticity and in 
the maintenance of neuronal integrity. Folate is a cofactor 
in one-carbon metabolism, during which it promotes the 
regeneration of methionine from homocysteine, a highly 
reactive sulfur-containing amino acid. Methionine can then 
be converted to S-adenosylmethionine, the principal methyl 
donor in most biosynthetic methylation reactions. At the 
cellular level, folate deficiency and hyperhomocysteinemia 
exert multiple detrimental effects. These include induction 
of DNA damage, misincorporation of uracil into DNA and 
altered patterns of DNA methylation. Low folate and elevated 
homocysteine levels increase the generation of reactive 
oxygen species, and contribute to excitotoxicity and mito-
chondrial dysfunction, which might lead to apoptosis. Strong 
epidemiological and experimental evidence links derange-
ments of one-carbon metabolism to vascular, neurodegen-
erative, and neuropsychiatric disease, in particular cerebral 
ischemia, Alzheimer’s dementia, and depression.33 Therefore, 
we believe it would be useful to incorporate treatment with 
folic acid into neuronal rehabilitation therapy.
Ginkgo biloba
Ginkgo bilboa, a plant extract, has had controversial results 
in AD patients.34 However, some studies have shown a neu-
roprotective effect (attributed to its high flavonoid content)35 
and an antioxidant action.36 Although it has been suggested 
that the use of Ginkgo biloba has no benefit in AD patients, 
there exists some evidence for a beneficial effect from EGb 
761 extract. Ginkgo biloba leaves contain a unique kind of 
flavonoid, and are harvested in South Korea, Japan, and 
France.37
Studies have demonstrated that β-amyloid peptide treat-
ment induces free radical production and increased glucose 
uptake, apoptosis, and cell death in PC12 nerve cells. 
  Addition of a standardized extract of Ginkgo biloba leaves, 
ie, EGb 761, together with β-amyloid peptide prevented 
β-amyloid peptide-induced free radical production, increased 
glucose uptake, apoptosis, and cell death, in a dose-dependent 
manner, However, pretreatment of these nerve cells with 
EGb 761 did not prevent β-amyloid peptide-induced tox-
icity, although it did prevent β-amyloid peptide-induced 
reactive oxygen species generation. Moreover, the terpene 
and flavonoid-free EGb 761 extract, HE 208, although able 
to inhibit a β-amyloid peptide-induced increase in glucose 
uptake, failed to protect the cells against β-amyloid peptide-
induced apoptosis and cytotoxicity. These results indicate 
that the terpenoid and flavonoid constituents of EGb 761, 
probably acting in combination with other components 
present in HE 208, are responsible for rescuing neuronal 
cells from β-amyloid peptide-induced apoptosis and cell 
death, their mechanism of action being distinct from their 
antioxidant properties.
Because pre- and post-treatment with EGb 761 does 
not protect cell-induced neurotoxicity, the possibility 
that EGb 761 interacts directly with β-amyloid peptide Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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was   investigated. Indeed, in vitro reconstitution studies 
  demonstrated that EGb 761 inhibits, in a dose-dependent 
manner, the formation of β-amyloid peptide-derived dif-
fusible neurotoxic soluble ligands, which are thought to be 
involved in the pathogenesis of AD.38 Importantly, Ginkgo 
biloba acts as a protective agent against the formation of 
amyloid fibrils, and this effect involves the MAP kinase 
cascade, SIRT1, and beta NFκ.39
Resveratrol
Phytophenols can be arbitrarily divided into the single-ring 
phenolic acids, the bisphenols, which include stilbenes, 
tricyclic phenols (flavonoids), and their subclasses, and 
the oligomeric and polymeric species, proanthocyanidins 
and anthocyanidins. Phytophenol precursors and stilbenes, 
including resveratrol and its analogs and conjugates, appear 
to have a preventive and possibly therapeutic role in athero-
sclerosis and certain neoplastic and inflammatory conditions. 
These molecules probably act as free radical scavengers, and 
might selectively interfere with multiple factors affecting cell 
division in rapidly and abnormally proliferative mammalian 
cells. There have been a number of studies published on the 
natural occurrence, extraction methods, bioavailability, ana-
lytical detection, and metabolism of resveratrol, as well as its 
effects on cancer, the inflammation process,   atherosclerosis, 
and neurons.
Grape extracts are a convenient source of salutary 
  phytochemicals to supplement currently available occidental 
food. Resveratrol could be added in biosignificant amounts 
to these extracts if extraction, content, and quality control 
issues are instituted.40
Resveratrol and catechin have been shown to be protec-
tive against β-amyloid peptide in PC12 cells. Many envi-
ronmental factors, including antioxidants, metal ions, and 
proteoglycans can modify β-amyloid peptide (1–41) toxicity 
in PC12 cells. Protection against reactive oxygen species 
toxicity is concentration-dependent for both resveratrol 
and catechin. This protective effect appears to be merely 
additive, rather than synergistic, and is unlikely to be due 
to antioxidant activity alone. The difference in chemical and 
biological activity shown by these compounds for several 
cell types, as well as the complex toxicity of β-amyloid 
peptide (1–41), may explain this synergistic protective 
effect. Utilization of different compounds with synergistic 
activity may improve the protective effect against complex 
toxicity mechanisms.41 A polyphenol-rich diet could help 
to maintain brain homeostasis, prevent oxidation, and keep 
neurons healthy.42
Nimesulide
Inflammatory processes in the brain are at the basis of the 
pathogenesis of AD, so nonsteroidal anti-inflammatory 
drugs have a protective effect in affected individuals. In a 
study in which quisqualic acid was injected into the right 
nucleus basalis of rats, excitotoxin induced cholinergic 
degeneration, an intense glial reaction, and production of 
inflammatory mediators. Seven days of treatment with intra-
muscular nimesulide 10 mg/kg/day strongly attenuated the 
microglial reaction, reduced the number of inducible nitric 
oxide synthase-positive cells, and completely abolished 
increased prostaglandin E2 formation. These data indicate 
that   cyclo-oxygenase-2 (COX-2) inhibitors have potential 
efficacy in the treatment of AD.43
COX-2 is involved in the inflammatory component of the 
ischemic cascade, playing an important role in delaying pro-
gression of brain damage. In one study, the neuroprotective 
effect of nimesulide was still evident 30 days after an isch-
emic episode, providing the first experimental evidence that 
COX-2 inhibitors confer long-lasting   neuroprotection. Oral 
administration of nimesulide was also able to reduce the extent 
of brain damage significantly, which suggests that its protec-
tive effects are independent of the route of   administration. 
This study confirms the ability of COX-2 inhibitors to reduce 
brain damage induced by cerebral ischemia, and indicates 
nimesulide can provide neuroprotection when administered 
for up to 24 hours after an ischemic event.44
Nimesulide has been withdrawn from the market in a 
number of countries because of its side effects, in particular 
the risk of hepatotoxicity at therapeutic doses. No English-
speaking country has approved its use, so there are limited 
data from Phase IV studies. There have been two reports of 
death in children as a result of Reye’s syndrome, a condi-
tion commonly associated with aspirin consumption in 
children under 12 years of age, and which causes numerous 
detrimental effects, especially to the brain and liver. In these 
cases, Reye’s syndrome was supposedly caused by consump-
tion of nimesulide. In addition, nimesulide was observed 
to have a dangerously rapid antipyretic effect in children, 
and is not recommended for reduction of fever under 40°C 
(approximately 101°F). However, physicians often succumb 
to parental pressure to lower their child’s fever. In countries 
like Finland, Spain, and Turkey, use of nimesulide has been 
prohibited in both children and adults, because of its hepa-
totoxicity, excessive antipyretic effect, and the potential to 
cause Reye’s syndrome. The European Drug Evaluation 
Agency is currently evaluating the status of nimesulide for 
an all-European approach.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Despite the adverse effects associated with nimesulide, 
it is beneficial if only given for a limited period of time and, 
like other nonsteroidal anti-inflammatory drugs, should not 
be used in children.
Recommendations
To date, we have followed two AD patients trying this 
therapy. Both patients were on drug treatment but showing 
no improvement. In addition to their existing treatment, they 
started our proposed therapy approximately one year ago, 
with satisfactory results so far.
Case 1
An 83-year-old woman was diagnosed with AD about 
10 years ago. At the time the proposed therapy was initiated, 
the patient presented with confusion about money, words, and 
the placing of objects, in addition to difficulty in remember-
ing certain activities and even recognizing her relatives. She 
had been taking rivastigmine, but after two years she started 
showing marked cognitive decline. After one year taking our 
proposed therapy, she now shows an improvement in memory, 
fluidity of language, and recognizes her relatives again. One 
of her sons said that the disease seems to have stopped, and 
that her brain appears to be regaining functionality.
Case 2
A man with a dramatic picture of AD had presented with 
very rapid cognitive decline, despite being treated with 
memantine. His wife made the decision to start this therapy, 
and his memory and conversational coherence has improved 
markedly. The only residual sign of the disease in this man 
is occasional mild aggression.
Discussion
Omega-3 acid could help restoration of neuronal membranes 
to the AD brain, allowing proper positioning of postsynaptic 
receptors, and enabling existing drug treatment to be more 
  effective. Tau dephosphorylation would restore axonal trans-
port of synaptic vesicles, and thus improve neurotransmitter 
release at the axon terminals. Once the membranes have 
been repaired, it would be important to induce the formation 
and maintenance of new synapses (Figure 1) by fluoxetine 
Alzheimer’s dendritic spine
Acetylcholine
Acetylcholinesterase
Acetylcholinesterase
inhibitor
Resveratrol
Ginkgo biloba
Folic acid
Re-connecting
synapses
Acetylcholinesterase
inhibitor
Serotonin
Reparing membranes
Omega-3
Serotonin
reuptake
Figure 1 Restoration of the dendritic spine. Dendrites damaged as a result of Alzheimer’s disease would result in abnormal neurotransmission because the receptors are not 
located in the right site as a result of the effect of neurodegeneration. The repair process is shown, beginning with omega-3 to allow repair of membranes and thus locate the 
receptors in the right places for effective neurotransmission. Serotonergic neurons would help in the formation of circuits due to the use of serotonin reuptake. Resveratrol 
and Ginkgo biloba serve as antioxidants and in the process of memory, respectively. Folic acid maintains the integrity of the newly repaired circuits.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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or escitalopram and folic acid. Serotonin regulates neuronal 
morphology and the reconnection between neurons,45 its path-
way interacts with that of acetylcholine,46 and it also has a role 
in memory impairment.47,48 A powerful antioxidant, such as 
resveratrol, and the activation of memory processes induced 
by Ginkgo bilboa, would improve the effects of membrane 
repair and formation of synapses. All of this together might 
then rehabilitate the AD brain to enable institution of drug 
treatment producing a better outcome (Figure 2). Ongoing 
neurodegenerative processes and the mechanisms of action 
of the drugs available have failed to cure AD,49 because they 
are brain enhancers.50
We believe this rehabilitating therapy in combination with 
drug treatment gives us a good possibility for improving the 
quality of life of both AD patients and their relatives, who 
also suffer the consequences of the disease. We propose an 
experimental strategy to evaluate the effects of this therapy 
(Figure 3). Of course, this should be tested in more AD 
patients in the near future.
We must bear in mind that AD has a slow progression 
and the neuronal damage occurs over a long period of time, 
to such an extent that it becomes impossible to prevent brain 
cell degeneration. At the last congress of The Society of 
Neuroscience at Chicago in 2009, the introduction of natural 
products to treat AD was recommended.
The alternative therapy we propose here could take over a 
year to have an effect, but it might be really helpful in patients 
with mild to moderate AD. However, in the advanced stages 
of the disease, this therapy would not be appropriate due to 
the large amount of neuronal loss. Although this therapy 
requires patience and cooperation from both patients and their 
relatives, we believe it provides a good option to improve 
treatment outcomes in AD.
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